Global Biotech Cooperations Logo

We’re a Contract Manufacturing Organization that brings medical innovation to life. A team with the right people, resources and facilities to help you manufacture biotechnological products to standards beyond expectations.

Manufacturing sites map

Our manufacturing sites

Located across Europe, the US and Asia, our cGMP-compliant facilities have the people and technology to create high-end solutions efficiently and at scale.

Contract manufacturing news

Advanced Therapies Week - GBTC

First conference 2023 – join us in Miami!

We are excited to kick off the 2023 conference season by exhibiting at the Advanced Therapies Week, 17-20 January 2023 in Miami. Meet our colleagues Carrie Bracco, Lauren Perdue, Stuart Macnab BSc (Hons), GCGI, PhD at booth #633 to learn about the Novartis Global Biotech Cooperation’s capabilities in advanced therapies and how we can support you in moving forward with your projects. We look forward to meeting you!

Watch the first edition of our webinar series as we discuss the journey of how Novartis GBTC has evolved into a Global Contract Manufacturing Organization over the last 40 years.

The facility will focus on Lenti and Adenoviral vectors, mainly for the contract manufacturing business. The new plant will be located at our Mengeš site in Slovenia and will become operational in early 2024. With this investment, we are addressing the worldwide growth in cell & gene therapies and increasing demand for capacity, driven by the global cell & gene therapy pipeline.

plant located at our Mengeš site in Slovenia

Basel, August 25, 2022 — Novartis today announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.

Read More

Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.

Read More

Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its support of the fill and finish of the Pfizer-BioNTech COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.

Read More

Contact us

We’re Novartis Contract Manufacturing Organization that helps customers around the world produce and manufacture life-changing biotechnological products.

Get in touch